EU regulators come up with a surprise rejection of Biogen Idec's (BIIB -2.7%) multiple sclerosis...


EU regulators come up with a surprise rejection of Biogen Idec's (BIIB -2.7%) multiple sclerosis drug Fampyra (Ampyra in the U.S.), which also knocks shares of the drug's developer Acorda Therapeutics (ACOR -16.7%).

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs